ChoA Pharmaceutical Co.Ltd - Asset Resilience Ratio
ChoA Pharmaceutical Co.Ltd (034940) has an Asset Resilience Ratio of 0.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ChoA Pharmaceutical Co.Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how ChoA Pharmaceutical Co.Ltd's Asset Resilience Ratio has changed over time. See 034940 net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down ChoA Pharmaceutical Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of ChoA Pharmaceutical Co.Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩199.74 Million | 0.32% |
| Total Liquid Assets | ₩199.74 Million | 0.32% |
Asset Resilience Insights
- Limited Liquidity: ChoA Pharmaceutical Co.Ltd maintains only 0.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ChoA Pharmaceutical Co.Ltd Industry Peers by Asset Resilience Ratio
Compare ChoA Pharmaceutical Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for ChoA Pharmaceutical Co.Ltd (2001–2025)
The table below shows the annual Asset Resilience Ratio data for ChoA Pharmaceutical Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.31% | ₩198.12 Million ≈ $134.26K |
₩64.68 Billion ≈ $43.83 Million |
-7.36pp |
| 2024-12-31 | 7.67% | ₩5.47 Billion ≈ $3.71 Million |
₩71.32 Billion ≈ $48.33 Million |
+1.84pp |
| 2023-12-31 | 5.83% | ₩4.33 Billion ≈ $2.93 Million |
₩74.22 Billion ≈ $50.30 Million |
-2.30pp |
| 2022-12-31 | 8.14% | ₩6.97 Billion ≈ $4.72 Million |
₩85.64 Billion ≈ $58.04 Million |
-4.53pp |
| 2021-12-31 | 12.66% | ₩10.19 Billion ≈ $6.91 Million |
₩80.51 Billion ≈ $54.56 Million |
+1.67pp |
| 2020-12-31 | 10.99% | ₩9.06 Billion ≈ $6.14 Million |
₩82.38 Billion ≈ $55.83 Million |
-5.71pp |
| 2019-12-31 | 16.70% | ₩14.49 Billion ≈ $9.82 Million |
₩86.74 Billion ≈ $58.78 Million |
+2.50pp |
| 2018-12-31 | 14.20% | ₩11.94 Billion ≈ $8.09 Million |
₩84.04 Billion ≈ $56.95 Million |
-0.40pp |
| 2017-12-31 | 14.60% | ₩12.20 Billion ≈ $8.27 Million |
₩83.52 Billion ≈ $56.60 Million |
+6.94pp |
| 2016-12-31 | 7.66% | ₩5.75 Billion ≈ $3.90 Million |
₩75.10 Billion ≈ $50.89 Million |
+4.18pp |
| 2015-12-31 | 3.48% | ₩2.59 Billion ≈ $1.75 Million |
₩74.35 Billion ≈ $50.38 Million |
-8.35pp |
| 2014-12-31 | 11.83% | ₩8.76 Billion ≈ $5.94 Million |
₩74.05 Billion ≈ $50.18 Million |
+1.96pp |
| 2013-12-31 | 9.87% | ₩6.99 Billion ≈ $4.73 Million |
₩70.82 Billion ≈ $47.99 Million |
-24.07pp |
| 2005-12-31 | 33.93% | ₩18.22 Billion ≈ $12.35 Million |
₩53.70 Billion ≈ $36.39 Million |
+28.22pp |
| 2004-12-31 | 5.71% | ₩2.16 Billion ≈ $1.46 Million |
₩37.72 Billion ≈ $25.56 Million |
-14.42pp |
| 2003-12-31 | 20.13% | ₩9.94 Billion ≈ $6.74 Million |
₩49.39 Billion ≈ $33.47 Million |
+2.88pp |
| 2002-12-31 | 17.25% | ₩10.46 Billion ≈ $7.09 Million |
₩60.60 Billion ≈ $41.07 Million |
-0.18pp |
| 2001-12-31 | 17.43% | ₩12.82 Billion ≈ $8.69 Million |
₩73.54 Billion ≈ $49.83 Million |
-- |
About ChoA Pharmaceutical Co.Ltd
ChoA Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea. The company produces approximately 200 medicines and health foods, including 30 internal ampoule products, such as Hepos, Fematin, Vasoclean, Mabis, etc. Its products include drugs for digestive, circulatory, and respiratory systems; vitamins, minerals, and nutrients; anti inflammation and analgesics; peripheral ne… Read more